Booster dose with the BNT162b2 vaccine in the population that received the complete immunization schedule for COVID-19 in Peru: A critical analysis of the current evidence

Carlos J. Toro-Huamanchumo, Jose A. Zavala-Loayza, Raisa N. Martinez-Rivera, Verónica Peralta, Eric R. Peña-Sanchez

Research output: Contribution to journalArticlepeer-review

Abstract

Background: In Peru, the current immunization schedule for COVID-19 includes BBIBP-CorV, BNT162B2 and ChAdOx1 nCoV-19 vaccines. Although the full immunization schedule is two doses, some countries have recently included a booster dose to their schedule. Methods: We conducted a search for scientific evidence on the efficacy and safety of booster vaccination with BNT162b2 vaccine in a population with a complete vaccination schedule for COVID-19 in Peru. Ev idence: Four evidence-based recommendation documents, one observational study and three ongoing phase III clinical trials were included for analysis. Conclusion: To date, there is insufficient evidence on the efficacy of adding a booster dose to the immunization schedule for COVID-19. The available evidence does not justify the use of a booster dose of BNT162B2 vaccine in a population that has previously received two doses of the aforementioned vaccines.

Translated title of the contributionBooster dose with the BNT162b2 vaccine in the population that received the complete immunization schedule for COVID-19 in Peru: A critical analysis of the current evidence
Original languageSpanish
Pages (from-to)70-78
Number of pages9
JournalRevista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo
Volume14
DOIs
StatePublished - 21 Oct 2021

Fingerprint

Dive into the research topics of 'Booster dose with the BNT162b2 vaccine in the population that received the complete immunization schedule for COVID-19 in Peru: A critical analysis of the current evidence'. Together they form a unique fingerprint.

Cite this